1 – 10 of 10
      - show: 10
- |
- sort: year (new to old)
        Close
        
            
    
    Embed this list
<iframe src=""
              width=""
              height=""
              allowtransparency="true"
              frameborder="0">
            </iframe>
        - 2025
- 
                        Mark
        Homeobox protein B6 and homeobox protein B8 control immune-cancer cell interactions in pancreatic cancer
    
    - Contribution to journal › Article
 
- 2018
- 
                        Mark
        Molecular and cellular mechanisms of chemoresistance in pancreatic cancer
    
    - Contribution to journal › Scientific review
 
- 2017
- 
                        Mark
        Development and In Vitro Characterization of a Gemcitabine-loaded MUC4-targeted Immunoliposome Against Pancreatic Ductal Adenocarcinoma
    
    - Contribution to journal › Article
 
- 
                        Mark
        Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine
    
    - Contribution to journal › Article
 
- 
                        Mark
        Pancreatic Ductal Adenocarcinoma : Current and Evolving Therapies
    
    - Contribution to journal › Scientific review
 
- 2015
- 
                        Mark
        Integrin β1, osmosensing, and chemoresistance in mouse ehrlich carcinoma cells
    
    - Contribution to journal › Article
 
- 2012
- 
                        Mark
        Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
    
    - Contribution to journal › Article
 
- 2009
- 
                        Mark
        Bacterial Deoxyribonucleoside Kinases Are Poor Suicide Genes in Mammalian Cells
    
    - Contribution to journal › Article
 
- 
                        Mark
        Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy
    
    - Contribution to journal › Article
 
- 2007
- 
                        Mark
        Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer
    
    - Contribution to journal › Article
 
